Cargando…
47D11 Antibody-Engineered Exosomes for Targeted Delivery of Remdesivir in Patients with COVID-19: Dream or Principle? (A Critical Editorial Study)
Along with the high transmission rate of coronavirus disease 2019 infection in the last few months, the morbidity and mortality rate of coronavirus disease 2019 has been increased among critically-ill patients, especially the elderly or the ones with immunodeficiencies. So, there is an urgent need t...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Atatürk University School of Medicine
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797761/ https://www.ncbi.nlm.nih.gov/pubmed/35950831 http://dx.doi.org/10.5152/eurasianjmed.2022.21116 |
_version_ | 1784860752515956736 |
---|---|
author | Daneshi, Nahid Esmaeilzadeh, Abdolreza Bahmaie, Nazila |
author_facet | Daneshi, Nahid Esmaeilzadeh, Abdolreza Bahmaie, Nazila |
author_sort | Daneshi, Nahid |
collection | PubMed |
description | Along with the high transmission rate of coronavirus disease 2019 infection in the last few months, the morbidity and mortality rate of coronavirus disease 2019 has been increased among critically-ill patients, especially the elderly or the ones with immunodeficiencies. So, there is an urgent need to develop more effective therapeutic agents through immunopathophysiological and immunotherapeutic-based strategies for these patients. Here, we hypothesize that mixing S1b-RBD-expressing mesenchymal stem cell-derived exosomes (which have been previously enriched with Remdesivir) with 47D11 antibody, can promisingly guarantee effective transferring of those targeted exosomes to the targeted microenvironment of coronavirus disease 2019 infection. In addition, it can induce their immunomodulatory properties, and anti-viral features, refraining from entrance of severe acute respiratory syndrome-related coronavirus-2 to angiotensin-converting enzyme 2-expressing cells. |
format | Online Article Text |
id | pubmed-9797761 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Atatürk University School of Medicine |
record_format | MEDLINE/PubMed |
spelling | pubmed-97977612023-01-03 47D11 Antibody-Engineered Exosomes for Targeted Delivery of Remdesivir in Patients with COVID-19: Dream or Principle? (A Critical Editorial Study) Daneshi, Nahid Esmaeilzadeh, Abdolreza Bahmaie, Nazila Eurasian J Med Letter to the Editor Along with the high transmission rate of coronavirus disease 2019 infection in the last few months, the morbidity and mortality rate of coronavirus disease 2019 has been increased among critically-ill patients, especially the elderly or the ones with immunodeficiencies. So, there is an urgent need to develop more effective therapeutic agents through immunopathophysiological and immunotherapeutic-based strategies for these patients. Here, we hypothesize that mixing S1b-RBD-expressing mesenchymal stem cell-derived exosomes (which have been previously enriched with Remdesivir) with 47D11 antibody, can promisingly guarantee effective transferring of those targeted exosomes to the targeted microenvironment of coronavirus disease 2019 infection. In addition, it can induce their immunomodulatory properties, and anti-viral features, refraining from entrance of severe acute respiratory syndrome-related coronavirus-2 to angiotensin-converting enzyme 2-expressing cells. Atatürk University School of Medicine 2022-10-01 /pmc/articles/PMC9797761/ /pubmed/35950831 http://dx.doi.org/10.5152/eurasianjmed.2022.21116 Text en © Copyright 2022 authors https://creativecommons.org/licenses/by/4.0/ Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. (https://creativecommons.org/licenses/by/4.0/) |
spellingShingle | Letter to the Editor Daneshi, Nahid Esmaeilzadeh, Abdolreza Bahmaie, Nazila 47D11 Antibody-Engineered Exosomes for Targeted Delivery of Remdesivir in Patients with COVID-19: Dream or Principle? (A Critical Editorial Study) |
title | 47D11 Antibody-Engineered Exosomes for Targeted Delivery of Remdesivir in Patients with COVID-19: Dream or Principle? (A Critical Editorial Study) |
title_full | 47D11 Antibody-Engineered Exosomes for Targeted Delivery of Remdesivir in Patients with COVID-19: Dream or Principle? (A Critical Editorial Study) |
title_fullStr | 47D11 Antibody-Engineered Exosomes for Targeted Delivery of Remdesivir in Patients with COVID-19: Dream or Principle? (A Critical Editorial Study) |
title_full_unstemmed | 47D11 Antibody-Engineered Exosomes for Targeted Delivery of Remdesivir in Patients with COVID-19: Dream or Principle? (A Critical Editorial Study) |
title_short | 47D11 Antibody-Engineered Exosomes for Targeted Delivery of Remdesivir in Patients with COVID-19: Dream or Principle? (A Critical Editorial Study) |
title_sort | 47d11 antibody-engineered exosomes for targeted delivery of remdesivir in patients with covid-19: dream or principle? (a critical editorial study) |
topic | Letter to the Editor |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797761/ https://www.ncbi.nlm.nih.gov/pubmed/35950831 http://dx.doi.org/10.5152/eurasianjmed.2022.21116 |
work_keys_str_mv | AT daneshinahid 47d11antibodyengineeredexosomesfortargeteddeliveryofremdesivirinpatientswithcovid19dreamorprincipleacriticaleditorialstudy AT esmaeilzadehabdolreza 47d11antibodyengineeredexosomesfortargeteddeliveryofremdesivirinpatientswithcovid19dreamorprincipleacriticaleditorialstudy AT bahmaienazila 47d11antibodyengineeredexosomesfortargeteddeliveryofremdesivirinpatientswithcovid19dreamorprincipleacriticaleditorialstudy |